Cytokinetics Files Q1 2025 10-Q, Details Financials
Ticker: CYTK · Form: 10-Q · Filed: May 6, 2025 · CIK: 1061983
| Field | Detail |
|---|---|
| Company | Cytokinetics Inc (CYTK) |
| Form Type | 10-Q |
| Filed Date | May 6, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, biotech
TL;DR
Cytokinetics Q1 10-Q filed. Financials and biz updates out. Notes and loans detailed.
AI Summary
Cytokinetics Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial performance and business activities, including details on its collaboration revenues and equity incentive plans. Key financial instruments mentioned include Convertible Senior Notes due 2027 and various loan agreements.
Why It Matters
This filing provides investors and stakeholders with an update on Cytokinetics' financial health and operational progress during the first quarter of 2025, impacting investment decisions.
Risk Assessment
Risk Level: medium — The company's financial health and future prospects are tied to its drug development pipeline and regulatory approvals, which carry inherent risks.
Key Numbers
- 20250331 — Reporting Period End Date (Quarterly financial reporting)
- 20250506 — Filing Date (Date the 10-Q was submitted to the SEC)
Key Players & Entities
- CYTOKINETICS INC (company) — Filer
- 20250331 (date) — Reporting Period End Date
- 20250506 (date) — Filing Date
- 350 OYSTER POINT BOULEVARD (address) — Company Business Address
- SOUTH SAN FRANCISCO (location) — Company Business Address City
- CA (location) — Company Business Address State
- 94080 (zip_code) — Company Business Address Zip
- cytk:TermLoanTrancheFourMember (financial_instrument) — Term Loan Tranche Four
- cytk:RPLoanAgreementMember (financial_instrument) — RP Loan Agreement
- cytk:ConvertibleSeniorNotesDue2027Member (financial_instrument) — Convertible Senior Notes Due 2027
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is March 31, 2025.
When was this 10-Q filing submitted to the SEC?
This 10-Q filing was submitted to the SEC on May 6, 2025.
What is the company's business address?
The company's business address is 350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA 94080.
What are some of the key financial instruments mentioned in the filing?
Key financial instruments mentioned include the Term Loan Tranche Four, RP Loan Agreement, and Convertible Senior Notes Due 2027.
Is there a specific license agreement mentioned?
Yes, the Bayer License Agreement is mentioned in the filing.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 6, 2025 regarding CYTOKINETICS INC (CYTK).